AcuraStem has received $3.7m to develop a small molecule treatment for amyotrophic lateral sclerosis (ALS), which it says could compete with Sanofiâs Riluzole and Mitsubishi Tanabeâs Radicava.
Original Article: AcuraStem targets small molecule ALS market